SCHEMBL4833633

SCHEMBL4833633

COC(=O)c1cc2ccc(Cl)cc2n1C

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.57
KDM4E B2RXH2 3/20 0.53
RXFP1 Q9HBX9 1/20 0.49
CYP1A2 P05177 1/20 0.46
CYP2C19 P33261 1/20 0.46
ABL1 P00519 1/20 0.44
UTS2R Q9UKP6 1/20 0.44
PTGS2 P35354 2/20 0.43
ALDH1A1 P00352 2/20 0.43
HPGD P15428 2/20 0.43
HSD17B10 Q99714 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
RAB9A P51151 1/20 0.42
GAA P10253 1/20 0.42
CASP1 P29466 1/20 0.42
CASP7 P55210 1/20 0.42
MTNR1A P48039 2/20 0.41
MTNR1B P49286 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29834934 1.00 L3MBTL1 (0.57) L3MBTL1KDM4ERXFP1CYP1A2CYP2C19
SCHEMBL4919697 0.88 L3MBTL1 (0.70) L3MBTL1KDM4ERXFP1PTGS2ALDH1A1
SCHEMBL31264263 0.84 NOD2 (0.53) L3MBTL1KDM4ECYP1A2CYP2C19UTS2R
SCHEMBL7626390 0.84 NOD2 (0.53) L3MBTL1KDM4ECYP1A2CYP2C19UTS2R
SCHEMBL3056564 0.83 L3MBTL1 (0.59) L3MBTL1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL7881270 0.83 L3MBTL1 (0.59) L3MBTL1KDM4ERXFP1ALDH1A1HPGD
SCHEMBL2828847 0.82 MCL1 (0.62) KDM4ERXFP1ALDH1A1HPGDHSD17B10
SCHEMBL31623400 0.82 MCL1 (0.62) KDM4ERXFP1ALDH1A1HPGDHSD17B10
SCHEMBL31623397 0.82 MCL1 (0.62) KDM4ERXFP1ALDH1A1HPGDHSD17B10
SCHEMBL4535733 0.81 L3MBTL1 (0.57) L3MBTL1KDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255129-A1 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indole-1-acetamide derivatives, their preparation and their application in therapeutics SANOFI-AVENTIS (FR) 2008-10-16 US disclosed
US-7405306-B2 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indole-1-acetamide derivatives, their preparation and their application in therapeutics SANOFI-AVENTIS (FR) 2008-07-29 US disclosed
US-20080076775-A1 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indole-1-acetamide derivatives, their preparation and their application in therapeutics SANOFI-AVENTIS (FR) 2008-03-27 US disclosed
US-7323467-B2 3-heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indole-1-acetamide derivatives, their preparation and their application in therapeutics SANOFI-AVENTIS (FR) 2008-01-29 US disclosed
US-20070219202-A1 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5 b]indole-1-acetamide derivatives, their preparation and their application in therapeutics SANOFI-AVENTIS (FR) 2007-09-20 US disclosed
US-7235554-B2 3-heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b] indole-1-acetamide derivatives, preparation and use thereof in medicaments SANOFI-AVENTIS (FR) 2007-06-26 US disclosed
US-20050124615-A1 3-heteroarly-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b] indole-1-acetamide derivatives, preparation and use thereof in medicaments SANOFI (FR) 2005-06-09 US disclosed
CN-1067988-C Indoloylguanidine derivatives SUMITOMO PHARMACEUTICS K K (JP) 2001-07-04 CN disclosed
US-6248772-B1 HYPOTENSIVE AGENTS; ANTIARRHYTHMIA AGENTS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2001-06-19 US disclosed
US-6169107-B1 USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS SUMITOMO PHARMACEUTICAL CO., LTD. (JP) 2001-01-02 US disclosed
CN-1051301-C Indoloylguanidine derivatives SUMITOMO PHARMA (JP) 2000-04-12 CN disclosed
EP-0622356-B1 Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange SUMITOMO PHARMA (JP) 1998-07-01 EP disclosed
CN-1136038-A Indoloylguanidine derivatives SUMITOMO PHARMACEUTICS K K (JP) 1996-11-20 CN disclosed
EP-0708091-A2 Indoloylguanidine derivatives SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1996-04-24 EP disclosed
CN-1106800-A Indoloylguanidine derivatives SUMITOMO PHARMA (JP) 1995-08-16 CN disclosed
EP-0622356-A1 Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1994-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080076775-A1 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indole-1-acetamide derivatives, their preparation and their application in therapeutics IDO1, IDO2, TPH1 L3MBTL1 3231/4885KDM4E 1207/4885RXFP1 127/4885
US-20050124615-A1 3-heteroarly-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b] indole-1-acetamide derivatives, preparation and use thereof in medicaments HRH4, IDO1, HTR4 L3MBTL1 4770/4885KDM4E 3162/4885RXFP1 1259/4885
US-20070219202-A1 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5 b]indole-1-acetamide derivatives, their preparation and their application in therapeutics IDO1, IDO2, TPH1 L3MBTL1 3402/4885KDM4E 975/4885RXFP1 102/4885
US-20080255129-A1 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-b]indole-1-acetamide derivatives, their preparation and their application in therapeutics IDO1, IDO2, TPH1 L3MBTL1 3231/4885KDM4E 1207/4885RXFP1 127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.